Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: A case report

paythelady.612 shared this article with you from Inoreader Botulinum toxin injection for Cockayne syndrome with muscle spasticity over bilateral lower limbs: A case report Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Jun 26;9(18):4728-4733. doi: 10.12998/wjcc.v9.i18.4728. ABSTRACT BACKGROUND: Cockayne syndrome (CS) is a rare inherited disease characterized by progressive motor symptoms including muscle weakness, joint contracture, ataxia, and spasticity. Botulinum neurotoxin type A has been used for conditions such as dystonia and spasticity, but it has rarely been used in patients with CS. CASE SUMMARY: We report a 6-year-and-9-mo old girl diagnosed with CS who received an injection of botulinum neurotoxin type A to manage her difficulty with walking. A total dose of 210 units of botulinum neurotoxin type A was administered into the bilateral tibialis posterior and gastrocnemius muscles. To evaluate the treatment effects on spasticity, joint contracture, pain, and ataxia, measurement tools including the Modified Ashworth Scale, the passive range of motion, the Faces Pain Scale-Revised, and the Scale for the Assessmen t and Rating of Ataxia, were employed. The first week after the injection, the Modified Ashworth Scale score for the plantar flexors and foot invertors improved bilaterally, along with advancements in the passive range of motion of the bilateral ankles and a lower score for the Faces Pain Scale-Revised. These treatment effects persisted to the 8th week post-injection, but returned to baseline values at the 12th week post-injection, except for the pain scale. CONCLUSION: Botulinum toxin injection can thus be considered as a treatment option for lower extremity spasticity, joint contracture, and pain derived from CS. PMID:34222439 | PMC:PMC8223832 | DOI:10.12998/wjcc.v9.i18.4728 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.